Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication.

• Status: Unknown status
• Trial end date: 2020-02-28
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to investigate the efficacy of a 7-day genotypic resistance-guided triple therapy, compared with empirical concomitant therapy, for first-line eradication of H. pylori.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Konstantopoulio-Patission General Hospital of Nea Ionia
• Treatments: Amoxicillin; Clarithromycin; Esomeprazole; Levofloxacin; Metronidazole; Ofloxacin; Rifabutin

Criteria

Inclusion Criteria:

• Consecutive outpatients aged ≥18 years with documented H. pylori infection. Mental and legal ability to provide written informed consent.

Exclusion Criteria:

• previous history of H. pylori eradication therapy

• history of allergies to the medications used

• previous esophageal or gastric surgery

• serious systemic disease

• pregnancy or lactation.